Post by
YukonJezza on Jan 07, 2021 9:00pm
Don Haut
well after Don Haut coming on board I bought some more ATE. Don Haut is no small potato.
Comment by
Ryeman40 on Jan 07, 2021 9:40pm
Interestingly Don Haut also worked at Monsato albeit at a early age. Monsato was also bought by Bayer for 66 billion in 2018.
Comment by
crow27 on Jan 07, 2021 10:47pm
He knows all the right people at Bayer. Connecting the dots does not seem that hard to do. ATE/ Don Haut/ Bayer. This guy is the deal maker for Bayer and now he is on ATE''s partnering advisory team. HELLO!!!!!! This is the beginning of some real traction for the stock. Hopefully everyone loaded up in that $3.40 - $3.50 range. The train is leaving the station folks.
Comment by
3burtc on Jan 08, 2021 2:14am
This isn't your everyday, run of the mill nsaid. This drug is a game changer. Otezla sod for 8 times revenue at 15 billion dollars! 346 revenue projected to be atleast double that. My guess is discussions with multiple companies are taking place as we speak.
Comment by
Doccole on Jan 08, 2021 6:37am
I believe it was highly important to get the news out before JP Morgan. I also think it's interesting to see that AskBio IPO was scrapped because BigPharma jumped in. BigPharma really waits to the last moment. the hydrogen sulfide platform offers so many opportunities for future drugs targeting inflammation. How much will OTENA fetch? Exciting times!
Comment by
Forestview on Jan 08, 2021 8:45am
Good point 3B, but if 346 has no revenue, and still needs to go through Phase 3, what's the impact to a potential acquisition?
Comment by
3burtc on Jan 08, 2021 8:52am
Of course it's not the same as an approved drug. But let's face it, it will be approved. The fact the they are willing to move the IP out of Holdings company will give nothing but confidence to shareholders and big pharma.
Comment by
Pragmatist on Jan 09, 2021 1:06pm
That is a great observation 10Bagger! I really like the IND-machine part. If ATE is talking with Bayer, then it might explain why ATE now wants to consolidate its IP suite with AHI, when it was perfectly happy with the existing arrangement for past partnering deals.
Comment by
themagicbox on Jan 08, 2021 9:36am
Youre right. Even the economic studies commisioned by ATE had similiar (and very conservative) first year estimates. Normally, its the analysts working for instos that do this. But ATE did the work for them, through a third party, to speed up their investing process. Dan and JLW are looking for an exit strategy, so JLW can get his emeritus on, and Dan can retire on his farm haha.
Comment by
3burtc on Jan 08, 2021 9:42am
Just my opinion but i think the FDA fast tracks 346. After all, they've been pounding the table about having these issues resolved.
Comment by
themagicbox on Jan 08, 2021 9:48am
I think that could happen for Otena/346 if it shows some indication for COVID related complications.